Bleselumab (ASKP 1240) is a humanised monoclonal antibody targeting CD40, characterised by high affinity (Kd = 0.24 nM), blocking the interaction between CD40 and its ligand CD40L and inhibiting immune responses, and is indicated for the prevention of organ transplant rejection.

Methods:
Peripheral blood mononuclear cells (PBMCs) from humans, cynomolgus monkeys, and rabbits were treated with Bleselumab at concentrations ranging from 0 to 1 μg/mL for 48 hours to evaluate its inhibitory effect on shCD154-induced PBMC proliferation.
Results:
Bleselumab effectively inhibited shCD154-induced PBMC proliferation in human, cynomolgus monkey, and rabbit samples within the 0–1 μg/mL concentration range.[2]

Methods:
In a cynomolgus monkey model, Bleselumab was administered via intravenous injection at doses of 0.1, 1, and 10 mg/kg to evaluate its effect on immune responses. [2]
Results:
Bleselumab inhibited the production of anti-TTx IgG and IgM in a concentration-dependent manner. [2]